Physician profile
Daniel Tsyvine
NPI 1245420330
$6,975.44
in general payments reported to CMS, 2019-2025
25 companies · $2,050 in 2025
The $2,050 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,364 · 2020: $682 · 2021: $1,106 · 2022: $714 · 2023: $546 · 2024: $514 · 2025: $2,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883 · Travel and Lodging: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.46 |
| Travel and Lodging | $1,225.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $1,621.04 | 2025 | Igt Devices Undivided, Coronary Other, Coronary Undivided |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $817.41 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $785.62 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $600.72 | 2019-2024 | Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $542.80 | 2019-2025 | |
| Medtronic, INC. | $382.03 | 2021-2025 | Onyx Frontier, Spiderfx, Linq II |
| Boston Scientific Corporation | $295.82 | 2020-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Synergy |
| Shockwave Medical, INC | $279.64 | 2022-2025 | |
| Amgen INC. | $272.13 | 2019-2025 | Repatha |
| Pfizer INC. | $269.88 | 2019-2024 | |
| Abiomed | $266.55 | 2021-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.62 | 2019-2023 | Jardiance |
| Kestra Medical Technology Services, INC. | $136.65 | 2023-2024 | Assure Wcd |
| Merck Sharp & Dohme LLC | $103.11 | 2021-2025 | Verquvo |
| Medtronic Vascular, INC. | $59.29 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $56.88 | 2024 | Kengreal |
| Amarin Pharma, INC. | $56.10 | 2019-2021 | |
| Penumbra, INC. | $50.97 | 2024 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $42.83 | 2019-2023 | Eliquis |
| Novo Nordisk INC | $30.28 | 2024 | Rybelsus, Ozempic |
| Stryker Corporation | $24.69 | 2025 | Artix Mt |
| Alnylam Pharmaceuticals INC. | $23.66 | 2024 | Onpattro |
| Abbott Laboratories | $20.62 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Esperion Therapeutics, INC. | $20.13 | 2023 | Nexletol |
| Lantheus Medical Imaging, INC. | $18.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tsyvine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.